Partnership / Collaboration · MENA · Announced 25 Jun 2022
Huadong Medicine → Julphar
Partnership / Collaboration deal between Huadong Medicine (China) and Julphar (United Arab Emirates), covering Liraglutide injection, announced 25 Jun 2022. Value: Undisclosed.
Parties: Huadong Medicine (China) → Julphar (United Arab Emirates)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- MENA — 17 countries (UAE, KSA, Egypt, Kuwait, Oman, Bahrain, etc.)
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Liraglutide injection — GLP-1 receptor agonist; biosimilar of Victoza® (different production process)
- Announced
- 25 Jun 2022
Our analysis
Why it matters
The GLP-1 land-grab in the Gulf started here, in 2022.
Long before the current wave of GLP-1 deals in our tracker (Adalvo→Avalon, Biocon→Tabuk, Daewoong→Arcera), Huadong and Julphar locked a local-manufacturing GLP-1 deal covering both diabetes and obesity across 17 MENA markets.
The full analysis is free to read with a work email on this page.
Source: Julphar news letter